{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:06:32Z","timestamp":1788397592563,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015235","name":"Supernus Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jpsychires.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:02:52Z","timestamp":1767772972000},"page":"211-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1054-5197","authenticated-orcid":false,"given":"Steven D.","family":"Targum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Formella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0642-5259","authenticated-orcid":false,"given":"Gianpiera","family":"Ceresoli-Borroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2026.01.006_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.31887\/DCNS.2006.8.2\/pbech","article-title":"Rating scales in depression: limitations and pitfalls","volume":"8","author":"Bech","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0447.1975.tb00002.x","article-title":"Quantitative rating of depressive states","volume":"51","author":"Bech","year":"1975","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0000000000001638","article-title":"Early response to antidepressant medications in adults with major depressive disorder: a naturalistic study and odds of remission at 14 weeks","volume":"43","author":"Belanger","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","article-title":"RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)","volume":"16","author":"Chandler","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cct.2011.04.006","article-title":"Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials","volume":"32","author":"Chen","year":"2011","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41386-020-00911-5","article-title":"Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders","volume":"46","author":"Cohen","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib9","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib10","first-page":"100","article-title":"Effects of psychotropic agents on primary depression","volume":"17","author":"Covi","year":"1981","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004714-200112000-00004","article-title":"The double-blind variable placebo lead-in period: results from two antidepressant clinical trials","volume":"21","author":"Faries","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41386-023-01600-9","article-title":"How should we design future mechanistic and\/or efficacy clinical trials?","volume":"49","author":"Fava","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","article-title":"Molecular pharmacology and neurobiology of rapid-acting antidepressants","volume":"59","author":"Gould","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib14","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/wps.21029","article-title":"The response pattern to SSRIs as assessed by the Montgomery-\u00c5sberg Depression Rating Scale: a patient-level meta-analysis","volume":"21","author":"Hieronymus","year":"2022","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jad.2020.11.066","volume":"281","author":"Hudgens","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.4088\/JCP.15m10253","article-title":"Evidence to support Montgomery-Asberg Depression Rating Scale administration every 24 hours to assess rapid onset of treatment response","volume":"77","author":"Johnson","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI126859","article-title":"Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation","volume":"129","author":"Kato","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.npp.1300341","article-title":"Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression","volume":"29","author":"Katz","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","article-title":"Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response","volume":"30","author":"Kobak","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1016\/j.euroneuro.2012.07.005","article-title":"Onset, time course and trajectories of improvement with antidepressants","volume":"22","author":"Lam","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jad.2021.03.053","article-title":"Validation of the McIntyre and Rosenblat Rapid Response Scale (MARRRS) in adults with treatment-resistant depression receiving intravenous ketamine treatment","volume":"288","author":"McIntyre","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1037\/h0021000","article-title":"Factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives","volume":"31","author":"Raskin","year":"1967","journal-title":"J. Consult. Psychol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005053-196901000-00010","article-title":"Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives","volume":"148","author":"Raskin","year":"1969","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-clinpsy-072120-014126","article-title":"Ketamine and the future of rapid-acting antidepressants","volume":"17","author":"Riggs","year":"2021","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mpr.79","article-title":"The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms","volume":"9","author":"Rush","year":"2000","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41380-020-0646-3","article-title":"Success and efficiency of phase 2\/3 adjunctive trials for MDD funded by industry: a systematic review","volume":"25","author":"Salloum","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41386-023-01647-8","article-title":"The why, when, where, how, and so what of so-called rapidly acting antidepressants","volume":"49","author":"Schatzberg","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamapsychiatry.2021.3204","article-title":"Association of single-blind placebo run-in periods with the placebo response in randomized clinical trials of antidepressants: a systematic review and meta-analysis","volume":"79","author":"Scott","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1038\/s41598-019-40693-5","article-title":"Discovery of NV-5138, the first selective brain mTORC1 activator","volume":"9","author":"Sengupta","year":"2019","journal-title":"Sci. Rep."},{"issue":"Suppl. 20","key":"10.1016\/j.jpsychires.2026.01.006_bib35","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2215-0366(16)00012-2","article-title":"Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study","volume":"3","author":"Shilyansky","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4088\/JCP.07m03780","article-title":"Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients","volume":"70","author":"Szegedi","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2009.04.014","article-title":"Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression","volume":"120","author":"Tadi\u0107","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpsychires.2017.09.009","article-title":"Early symptomatic improvement affects treatment outcome in a study of major depressive disorder","volume":"95","author":"Targum","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpsychires.2019.11.014","article-title":"Early score fluctuation and placebo response in a study of major depressive disorder","volume":"121","author":"Targum","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib42","first-page":"126","article-title":"NV-5138 a novel, direct activator of the mechanistic target of rapamycin complex 1 (mTORC1): a phase 1b randomized, double-blind, placebo-controlled single oral dose study in subjects with treatment-resistant depression (TRD)","volume":"44","author":"Targum","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jpsychires.2021.02.012","article-title":"Ecological momentary assessment as a measurement tool in depression trials","volume":"136","author":"Targum","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000457131","article-title":"A systematic review of the clinimetric properties of the 6-Item version of the Hamilton Depression Rating Scale (HAM-D6)","volume":"86","author":"Timmerby","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib45","first-page":"221","article-title":"Brief Psychiatric Rating Scale (BPRS) expanded version (4.0): scales, anchor points and administration manual","volume":"13","author":"Ventura","year":"1993","journal-title":"Int. J. Meth. Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00213-014-3765-1","article-title":"Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients","volume":"232","author":"Vermeiden","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.jpsychires.2026.01.006_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1135828","article-title":"Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants","volume":"14","author":"Yavorsky","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jpsychires.2026.01.006_bib49","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/NDT.S196533","article-title":"Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study","volume":"15","author":"Yuan","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395626000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:04:11Z","timestamp":1780862651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395626000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":49,"alternative-id":["S0022395626000063"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.01.006","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}